Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its fourth-quarter and full-year 2024 financial results announcement for February 27, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss financial results and business highlights. The presentation will be accessible through the company's Investor Relations website, with slides available during the call. A replay of the webcast will remain available until February 27, 2026.
Vericel (NASDAQ:VCEL), un leader nelle terapie avanzate per il mercato della medicina sportiva e della cura delle ustioni gravi, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 8:30 a.m. ET nello stesso giorno per discutere i risultati finanziari e i punti salienti aziendali. La presentazione sarà accessibile tramite il sito web delle Relazioni con gli Investitori dell'azienda, con le diapositive disponibili durante la chiamata. Una registrazione della trasmissione in diretta rimarrà disponibile fino al 27 febbraio 2026.
Vericel (NASDAQ:VCEL), un líder en terapias avanzadas para los mercados de medicina deportiva y atención de quemaduras severas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 27 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET el mismo día para discutir los resultados financieros y los aspectos destacados del negocio. La presentación estará disponible a través del sitio web de Relaciones con Inversores de la empresa, con diapositivas disponibles durante la llamada. Una repetición de la transmisión en vivo estará disponible hasta el 27 de febrero de 2026.
Vericel (NASDAQ:VCEL), 스포츠 의학 및 중증 화상 치료 시장을 위한 첨단 치료의 선두주자인 Vericel은 2025년 2월 27일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 오전 8시 30분 ET에 재무 결과 및 비즈니스 하이라이트에 대해 논의하기 위해 전화 회의 및 웹 캐스트를 개최합니다. 발표는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있으며, 전화 중에 슬라이드를 이용할 수 있습니다. 웹 캐스트의 재생은 2026년 2월 27일까지 가능합니다.
Vericel (NASDAQ:VCEL), un leader dans les thérapies avancées pour les marchés de la médecine sportive et des soins aux brûlures sévères, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 27 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire le même jour à 8h30 ET pour discuter des résultats financiers et des points forts de l'entreprise. La présentation sera accessible via le site Web des Relations Investisseurs de l'entreprise, avec des diapositives disponibles pendant l'appel. Une rediffusion du webinaire restera disponible jusqu'au 27 février 2026.
Vericel (NASDAQ:VCEL), ein führendes Unternehmen für fortschrittliche Therapien in den Bereichen Sportmedizin und schwerer Brandverletzungen, hat die Bekanntgabe seiner Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 auf den 27. Februar 2025 terminiert. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse und Geschäftshighlights zu besprechen. Die Präsentation wird über die Investor-Relations-Website des Unternehmens zugänglich sein, mit Folien, die während des Anrufs verfügbar sind. Eine Wiederholung des Webcasts wird bis zum 27. Februar 2026 verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until February 27, 2026.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2025 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When will Vericel (VCEL) report Q4 and full-year 2024 earnings?
What time is Vericel's (VCEL) Q4 2024 earnings call?
How can investors access Vericel's (VCEL) Q4 2024 earnings webcast?
How long will Vericel's (VCEL) Q4 2024 earnings webcast replay be available?
